Drug Combination Details
| General Information of the Combination (ID: C73328) | |||||
|---|---|---|---|---|---|
| Name | Genistein NP Info | + | 1,25-dihydroxyvitamin D3 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CYP24A1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Genistein potentiates the antiproliferative actions of 1,25(OH)2D3 in DU145 cells by two mechanisms: (i) an increase in the half-life of 1,25(OH)2D3 due to the direct inhibition of CYP24 enzyme activity and (ii) an amplification of the homologous up-regulation of VDR. | |||||
